Pura Vida Investments, LLC Incyte Corp Transaction History

Pura Vida Investments, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $2.04 Million - $2.56 Million	30,400 New	30,400 $2.44 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $3.25 Million - $3.93 Million	-49,278 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $3.12 Million - $3.65 Million	49,278 New	49,278 $3.62 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $8.85 Million - $9.69 Million	-110,750 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$76.02 - $100.5 $8.42 Million - $11.1 Million	110,750 New	110,750 $9 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $2.06 Million - $2.45 Million	-28,318 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$63.56 - $88.17 $1.71 Million - $2.37 Million	-26,889 Reduced 48.71%	28,318 $2.44 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $2.35 Million - $2.81 Million	40,207 Added 268.05%	55,207 $3.51 Million
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $1.25 Million - $1.51 Million	15,000 New	15,000 $0
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $4.68 Million - $5.83 Million	-50,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $5.46 Million - $6.91 Million	50,000	50,000 $5.84 Billion

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Pura Vida Investments, LLC with notifications on news.